Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- Iqirvo (elafibranor)
- nilotinib
Interactions between your drugs
nilotinib elafibranor
Applies to: nilotinib, Iqirvo (elafibranor)
Elafibranor may reduce the blood levels of nilotinib. In some cases, this may make the medication less effective in treating your cancer. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
nilotinib food
Applies to: nilotinib
Do not consume grapefruit or grapefruit juice during treatment with nilotinib unless directed otherwise by your doctor. Grapefruit juice can increase the blood levels of nilotinib to dangerous levels, increasing the risk of an irregular heart rhythm that may be serious. You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment with nilotinib. Food may also increase the blood levels of nilotinib. Therefore, you should take nilotinib on an empty stomach, meaning no food should be eaten for at least two hours before or one hour after taking nilotinib. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Ocaliva
Ocaliva may be used to treat primary biliary cholangitis (PBC) in adults without cirrhosis or with ...
Cosentyx
Cosentyx (secukinumab) is used to treat plaque psoriasis, psoriatic arthritis, ankylosing ...
Livdelzi
Livdelzi (seladelpar) is an oral prescription medicine that may be used to treat primary biliary ...
Actigall
Actigall is used for gallbladder disease, primary biliary cholangitis
Urso Forte
Urso Forte is used for gallbladder disease, primary biliary cholangitis
Reltone
Reltone is used for gallbladder disease, primary biliary cholangitis
Obeticholic acid
Obeticholic acid (brand name Ocaliva) may be used to treat primary biliary cholangitis (PBC) in ...
Ursodiol
Ursodiol information from Drugs.com, includes Ursodiol side effects, interactions and indications.
Seladelpar
Seladelpar is used to treat primary biliary cholangitis (PBC) in adults. It is a once-daily capsule ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.